Potent and selective irreversible inhibitor of Cdc25 dual specificity phosphatases (Ki
values are 32, 96 and 40 nM for inhibition of Cdc25A, -B and -C respectively). Displays 125 - 180-fold selectivity over VH1-related dual-specificity phosphatase and protein tyrosine phosphatase 1b. Inhibits carcinoma cell growth and blocks G2
/M phase transition in vitro
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
NAD(P)H:Quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
Han et al.
Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors.
Lazo et al.
Quinone-induced Cdc25A inhibition causes ERK-dependent connexin phosphorylation.
Melchheier et al.